



PTO/SB/08B (09-06)

Substitute for form 144B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/561,449		
		Filing Date	December 20, 2005		
		First Named Inventor	Luc Bouwens et al.		
		Art Unit	1647		
		Examiner Name	Daniel C. Gamett		
Sheet	1	of	3	Attorney Docket Number	BOUW3001/JEK
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ₂
		European Search Report dated November 16, 2007 relating to European Application EP 04 73 7673			
		RAMIYA K. VIJAYAKUMAKUMAR ET AL., "Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells", <i>Nature Medicine</i> , <i>Nature America</i> , Vol. 6, No. 3, March 2000 (2000-03) pages 278-282, XP000864764			
		HIROSATO MASHIMA ET AL., "Betacellulin and Activin A Coordinately Convert Amylase-secreting Pancreatic AR42J Cells into insulin-secreting Cells", <i>Journal of Clinical Investigation</i> , Vol. 97, No. 7, April 1 1996 (1996-04-01), pages 1647-1657, XP000670303			
		KI-HO SONG ET AL., "In vitro transdifferentiation of adult pancreatic acinar cells into insulin-expressing cells", <i>Biochemical and Biophysical Research Communications</i> , Vol. 316, No. 4, April 16, 2004 (2004-04-16), pages 1094-1100, XP004496901			
		YELENA GUZ ET AL., "Regeneration of Pancreatic β Cells from Intra-Islet Precursor Cells in an Experimental Model of Diabetes", <i>Endocrinology</i> , Vol. 142, No. 11, November 2001, pages 4956-4968, (available at http://www.endo.endojournals.org)			
		I. ROOMAN ET AL., "Modulation of rat pancreatic acinoductal transdifferentiation and expression of PDX-1 in vitro", <i>Diabetologia</i> , Springer-Verlag 2000, Vol. 43, pages 907-914			
		ILSE ROOMAN ET AL., "Mitogenic Effect of Gastrin and Expression of Gastrin Receptors in Duct-like Cells of Rat Pancreas", <i>Gastroenterology</i> , Vol. 123, 2001, pages 940-949			
		ILSE ROOMAN ET AL., "Gastrin Stimulates β Cell Neogenesis and Increases Islet Mass From Transdifferentiated but Not From Normal Exocrine Pancreas Tissue", <i>Diabetes</i> , Vol. 51, March 2002, pages 686-690			
		DANLING GU ET AL., "Endocrine/Exocrine Intermediate Cells in Streptozotocin-Treated INS-1FN- γ Transgenic Mice", <i>Biomedische Bibl</i> , Vol. 15, No. 3, 1997, pages 246-250			
		YUEHUA JIANG ET AL., "Pluripotency of mesenchymal stem cells derived from adult marrow", <i>Nature</i> , Vol. 418, July 2002, pages 41-49			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 144B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/561,449
				Filing Date	December 20, 2005
				First Named Inventor	Luc Bouwens et al.
				Art Unit	1647
				Examiner Name	Daniel C. Gamett
Sheet	2	of	3	Attorney Docket Number	BOUW3001/JEK
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ₂
		CORENTIN CRAS-MÉNEUR ET AL., "Epidermal Growth Factor Increases Undifferentiated Pancreatic Embryonic Cells In Vitro: A Balance Between Proliferation and Differentiation", <u>Diabetes</u> , Vol. 50, July 2001, pages 1571-1579			
		PÄIVI J. MIETTINAN ET AL., "Impaired migration and delayed differentiation of pancreatic islet cells in mice lacking EGF-receptors", <u>Development</u> , Vol. 127, 2000, pages 2617-2627			
		KOJI YAMAMOTO ET AL., "Recombinant Human Betacellulin Promotes the Neogenesis of β -Cells and Ameliorates Glucose Intolerance in Mice With Diabetes Induced by Selective Alloxan Perfusion", <u>Diabetes</u> , Vol. 40, December 2000, pages 2021-2027			
		EUGENIO BERTELLI ET AL., "Intermediate endocrine-acinar pancreatic cells in duct ligation conditions", <u>American Physiological Society</u> , Vol. 273, 1997, pages 1641-1649			
		SUSAN BONNER-WEIR ET AL., " <i>In vitro</i> cultivation of human islets from expanded ductal tissue", <u>PNAS</u> , Vol. 97, No. 14, July 5, 2000, pages 7999-8004			
		LUC BOWENS, "Transdifferentiation Versus Stem Cell Hypothesis for the Regeneration of Islet Beta-Cells in the Pancreas", <u>Microscopy Research And Technique</u> , Vol. 43, 1998, pages 332-336			
		LUC BOWENS ET AL., "Islet cell neogenesis in the pancreas", <u>Biomedische-Bibl</u> , 1996, Vol. 427, pages 553-560			
		STEPHEN J. BRAND ET AL., "Pharmacological Treatment of Chronic diabetes by Stimulating Pancreatic β -Cell Regeneration with Systemic Co-administration of EGF and Gastrin", <u>Pharmacology & Toxicology</u> , Vol. 91, 2000, pages 414-420			
		JEAN BUTEAU ET AL., "Glucagon-Like Peptide 1 Induces Pancreatic β -Cell Proliferation Via Transactivation of the Epidermal Growth Factor Receptor", <u>Diabetes</u> , Vol. 52, January 2003, pages 124-132			
		DANIEL C. DRUCKER, "Glucagon-Like Peptides: Regulators of Cell Proliferation, Differentiation, and Apoptosis", <u>Molecular Endocrinology</u> , Vol. 17, No. 2, 2003, pages 151-171			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**